Press Releases

Date Title and Summary  
Toggle Summary Geron Enhances Oncology Expertise to Advance Corporate Objectives
MENLO PARK, Calif. , July 18, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced the appointments of Sharon McBain as Vice President, Global Regulatory Affairs and Lynn Bodarky as Vice President, Business Development. These appointments further enhance the Company’s oncology
Toggle Summary Geron Appoints Vice President, Human Resources
MENLO PARK, Calif. , June 20, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced the appointment of Shannon Odam as Vice President, Human Resources. Ms. Odam joins other recently recruited senior leadership to further strengthen the organization as it expands its operations
Toggle Summary Geron Reports Two Imetelstat Data Presentations at European Hematology Association Annual Congress
Updated 8-week RBC-TI rate for the Phase 2 portion of IMerge increased to 42%, from 37% in December 2018 Updated 24-week RBC-TI rate for the Phase 2 portion of IMerge increased to 29%, from 26% in December 2018 Statistical analyses comparing IMbark clinical trial data to closely matched real-world
Toggle Summary Geron to Webcast KOL Event on June 25, 2019
MENLO PARK, Calif. , June 10, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that the Company will webcast an event on June 25, 2019 , featuring key opinion leaders (KOLs) who are authors of imetelstat data presentations being made at the 24th Annual Congress of the
Toggle Summary Geron Announces Two Presentations on Imetelstat at Upcoming European Hematology Association Annual Congress
MENLO PARK, Calif. , May 16, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that two abstracts containing clinical data and analyses related to imetelstat, the Company’s first-in-class telomerase inhibitor, have been accepted for presentation at the 24th European
Toggle Summary Geron Provides Imetelstat Program Update
Conference Call Scheduled for 9:00 a.m. ET today MENLO PARK, Calif. , May 16, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today provided an update to its 2019 corporate objectives for the imetelstat program. “2019 is off to a good start with the imetelstat IND transfer now complete,
Toggle Summary Geron Continues to Build Senior Leadership of Its Development Team
MENLO PARK, Calif. , May 16, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that it is continuing to build the senior leadership of its development team with the addition of a Vice President, Biometrics, and a Vice President, Manufacturing.
Toggle Summary Geron Corporation Reports First Quarter 2019 Financial Results
MENLO PARK, Calif. , May 02, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported financial results for the first quarter ended March 31, 2019 . As of the quarter-end, the Company had approximately $170 million in cash and marketable securities, which is sufficient to support
Toggle Summary Geron Expands Senior Leadership of Its Development Team
MENLO PARK, Calif. , April 18, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced an expansion of its development team’s senior leadership with the addition of three highly experienced professionals for key functional areas. Their oncology and drug development expertise will
Toggle Summary Geron to Present at Needham Healthcare Conference
MENLO PARK, Calif. , April 02, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett , M.D., Chairman and Chief Executive Officer, is scheduled to present a company overview at the 18th Annual Needham Healthcare Conference in New York at 3:30 p.m.